Connect with us

Business

On a roll, Merck blazes through a new segment of the biomarker trail – Endpoints News

Merck has notched an approval for using Keytruda to treat a biomarker-based subset of first-line colorectal cancer patients with unresectable or metastatic tumors, as the pharma giant continues to find new niches for its blockbuster PD-1 star. The OK is signi…

Published

on

post featured image

Mer­ck has notched an ap­proval for us­ing Keytru­da to treat a bio­mark­er-based sub­set of first-line col­orec­tal can­cer pa­tients with un­re­sectable or metasta­t­ic tu­mors, as the phar­ma gi­a…

Click here to view the original article.